Prognostic Significance of Serum Beta-2 Microglobulin in Patients with Non-Hodgkin Lymphoma (original) (raw)
Related papers
Beta 2 Microglobulin as a Marker of Diagnosis and Disease Severity in Non Hodgkin Lymphoma
2015
Lymphoma, which can be described as proliferations of lymphoid cells arising as discrete tissue masses, is broadly divided into Non – Hodgkin Lymphoma (NHL) and Hodgkin disease. Majority of malignant lymphoma are found to be NHL. Beta-2 microglobulin (B2M) is synthesized in all nucleated cells and forms the light chain subunit of the major histocompatibility complex class I antigen. Despite its potential role as a convenient and non-invasive prognostic indicator in malignant lymphomas, the influence of serum B2M is currently underestimated, and therapeutic decision making is rarely affected by this marker. Objective:To find out the levels of B2M in patients of NHL and to observe if the levels are significantly correlated with the stage of the disease, performance status as denoted by ECOG performance scale, International prognostic index(IPI) evaluated at the time of diagnosis, and thereby, to the severity of disease. Methods: 30 patients with confirmed diagnosis of NHL and 30 age a...
The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma
Haematologica, 2002
Background and Objectives. Serum β 2 -microglobulin (sβ 2 m) is an established prognostic factor for multiple myeloma and non-Hodgkin's lymphoma, but only limited data suggest an adverse prognostic significance for Hodgkin's lymphoma (HL). This study was undertaken to examine the impact of sβ 2 m on the prognosis of patients with HL.
BACKGROUND: Although serum beta-2 microglobulin (B2M) represents a key variable for symptomatic multiple myeloma (MM) prognostication, its role in predicting the risk of progression of asymptomatic MM to symptomatic disease has not been explored. METHODS: This study was bases on a consecutive series of 148 patients with asymptomatic MM and explored the cumulative probability of progression to symptomatic MM as the primary endpoint. RESULTS: In univariate analysis, a serum B2M level >2.5 mg/L was associated with an increased probability of disease progression (5-year risk, 64.5%; P < .001) along with serum monoclonal component (sMC) (P < .001), urinary monoclonal component (uMC) (P < .001), and bone marrow plasma cells (BMPCs) (P < .001). In multivariate analysis, serum B2M was selected as an independent predictor of progression (hazard ratio, 3.30; P¼.002). Serum B2M was combined with sMC, uMC, and BMPC to create a risk-stratification model based on 4 groups with different risk of progression: very low (5-year risk, 0%), low-intermediate (5-year risk, 19.6%), high-intermediate (5-year risk, 60.7%), and high (5-year risk, 80.7%). The model that included serum B2M along with sMC, uMC, and BMPC was able to predict disease progression better than the model that was based on sMC, uMC, and BMPC without serum B2M (C statistics, 0.760 vs 0.726). CONCLUSIONS: The current results indicated that 1) serum B2M is an independent predictor of asymptomatic MM progression, and 2) serum B2M adds prognostic information when combined with the most widely used prognosticators of asymptomatic MM progression.
Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma
Cancer, 2010
BACKGROUND: Although serum beta-2 microglobulin (B2M) represents a key variable for symptomatic multiple myeloma (MM) prognostication, its role in predicting the risk of progression of asymptomatic MM to symptomatic disease has not been explored. METHODS: This study was bases on a consecutive series of 148 patients with asymptomatic MM and explored the cumulative probability of progression to symptomatic MM as the primary endpoint. RESULTS: In univariate analysis, a serum B2M level >2.5 mg/L was associated with an increased probability of disease progression (5-year risk, 64.5%; P < .001) along with serum monoclonal component (sMC) (P < .001), urinary monoclonal component (uMC) (P < .001), and bone marrow plasma cells (BMPCs) (P < .001). In multivariate analysis, serum B2M was selected as an independent predictor of progression (hazard ratio, 3.30; P ¼.002). Serum B2M was combined with sMC, uMC, and BMPC to create a risk-stratification model based on 4 groups with different risk of progression: very low (5-year risk, 0%), low-intermediate (5-year risk, 19.6%), high-intermediate (5-year risk, 60.7%), and high (5-year risk, 80.7%). The model that included serum B2M along with sMC, uMC, and BMPC was able to predict disease progression better than the model that was based on sMC, uMC, and BMPC without serum B2M (C statistics, 0.760 vs 0.726). CONCLUSIONS: The current results indicated that 1) serum B2M is an independent predictor of asymptomatic MM progression, and 2) serum B2M adds prognostic information when combined with the most widely used prognosticators of asymptomatic MM progression.
Pakistan Journal of Health Sciences
Indolent and aggressive hematopoietic cancer shed lot of Beta 2 microglobulin in interstitial fluid thus increasing the level of B2M in hematological malignancies. Objectives: To set forward B2M as potential biomarker for the detection and stage of malignant lymphoma. Methods: Serum of newly diagnosed Hodgkin’s and non-Hodgkin’s lymphoma patients presented to physician prior to any surgical or medicinal treatment were collected and evaluated through sandwich type of ELISA for the possible elevation of B2M. B2M concentrations in healthy individual’s serum (control group) were also detected. Mean values of B2M in all three groups were compared by applying one-way analysis of variance to determine the significant difference. Results: The serum of Hodgkin’s Lymphoma patients depicted 5 folds higher B2M concentration than the healthy subjects, while NHL showed more concentration of circulating B2M where it was 6-fold higher than healthy subjects. Moreover, the advanced stage of the dise...
Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma
Hematological Oncology, 2006
Sixty-eight previously untreated patients with primary gastric non-Hodgkin's lymphoma (NHL) available for analysis, were entered in a study in which the prognostic significance of serum beta 2 microglobulin levels were evaluated.The serum beta 2 microglobulin was the most significant prognostic factor. Patients with high levels (> 3.5 μg/mL) had a relapse-free survival (RFS) of 36 months, while the median RFS has not been reached in patients with normal levels (p<0.001). The 5-year survival was 80 per cent for patients with normal levels, statistically significant when compared to patients with high levels: 38 per cent (p> 0.001).Serum beta 2 microglobulin should be included in the initial staging of patients with primary extranodal NHL and patients with high levels should be treated more aggressively.
Clinical significance of serum beta-2 microglobulin levels in hematological malignancies
The KITAKANTO Medical Journal, 1997
The clinical significance of serum beta-2 microglobulin (SƒÀ2M) levels in hematological malignancies and of the ratio of measured ƒÀ2M value to calculated ƒÀ2M (ƒÀ2M M/CTD ratio) from the serum creatinine level for assessing renal function were examned. The levels of SƒÀ2M in patients with multiple myeloma (MM), polycythemia vera (PV), and renal failure were markedly increased. The ƒÀ2M M/CTD ratio was increased in MM and PV patients, but was not increased in renal failure patients, suggesting that the ƒÀ2M M/CTD ratio is useful for distinguishing between MM and renal failure.